Details for New Drug Application (NDA): 208390
✉ Email this page to a colleague
The generic ingredient in TICAGRELOR is ticagrelor. There are twenty-one drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the ticagrelor profile page.
Summary for 208390
| Tradename: | TICAGRELOR |
| Applicant: | Watson Labs Inc |
| Ingredient: | ticagrelor |
| Patents: | 0 |
Pharmacology for NDA: 208390
| Mechanism of Action | Cytochrome P450 3A4 Inhibitors P-Glycoprotein Inhibitors P2Y12 Receptor Antagonists |
| Physiological Effect | Decreased Platelet Aggregation |
Suppliers and Packaging for NDA: 208390
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TICAGRELOR | ticagrelor | TABLET;ORAL | 208390 | ANDA | Teva Pharmaceuticals, Inc. | 0480-2688 | 0480-2688-06 | 60 TABLET, FILM COATED in 1 BOTTLE (0480-2688-06) |
| TICAGRELOR | ticagrelor | TABLET;ORAL | 208390 | ANDA | Teva Pharmaceuticals, Inc. | 0480-2695 | 0480-2695-06 | 60 TABLET, FILM COATED in 1 BOTTLE (0480-2695-06) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 60MG | ||||
| Approval Date: | Sep 4, 2018 | TE: | AB | RLD: | No | ||||
| Regulatory Exclusivity Expiration: | Oct 28, 2025 | ||||||||
| Regulatory Exclusivity Use: | PATENT CHALLENGE | ||||||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 90MG | ||||
| Approval Date: | Sep 4, 2018 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
